S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
S&P 500   3,831.70 (+0.06%)
DOW   31,063.14 (-1.08%)
QQQ   314.93 (+0.67%)
AAPL   122.80 (+1.50%)
MSFT   233.03 (+1.76%)
FB   262.09 (+2.91%)
GOOGL   2,026.49 (+0.52%)
AMZN   3,071.54 (+0.47%)
TSLA   672.48 (-1.43%)
NVDA   545.85 (+2.55%)
BABA   239.76 (-0.17%)
CGC   32.42 (-2.38%)
GE   12.63 (-1.02%)
MU   91.20 (+3.50%)
NIO   46.10 (-1.52%)
AMD   84.02 (+1.94%)
T   28.00 (-2.20%)
F   11.72 (-0.34%)
ACB   10.65 (-1.57%)
DIS   189.03 (-1.02%)
BA   211.68 (-2.20%)
NFLX   540.54 (-1.13%)
BAC   34.94 (-2.76%)
Log in
NYSEAMERICAN:SYN

Synthetic Biologics Stock Forecast, Price & News

$0.67
-0.02 (-3.07 %)
(As of 02/26/2021 02:19 PM ET)
Add
Compare
Today's Range
$0.65
Now: $0.67
$0.71
50-Day Range
$0.32
MA: $0.37
$0.50
52-Week Range
$0.25
Now: $0.67
$1.70
Volume257,165 shs
Average Volume28.89 million shs
Market Capitalization$13.37 million
P/E RatioN/A
Dividend YieldN/A
Beta2.29
Synthetic Biologics, Inc., a clinical-stage company develops therapeutics to treat gastrointestinal diseases in the United States. Its lead product candidates include SYN-004 that has completed Phase II clinical trial designed to degrade commonly used intravenous beta-lactam antibiotics in gastrointestinal tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease in allogeneic hematopoietic cell transplant recipients. The company is also developing SYN-010 that is in Phase IIb/III clinical trial to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation; and SYN-020, an early-stage oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, its clinical stage products include SYN-006 and SYN-007 for the prevention of CDI, overgrowth of pathogenic organisms, and AMR; and SYN-005 for the prevention and treatment of pertussis. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company is headquartered in Rockville, Maryland.
Synthetic Biologics logo

Headlines

Synthetic Biologics, Inc. to Host Earnings Call
November 10, 2020 |  finance.yahoo.com
Synthetic Biologics Inc.
November 7, 2020 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:SYN
CUSIPN/A
Phone+1-734-3327800
Employees11
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.35) per share

Profitability

Net Income$-15,300,000.00

Miscellaneous

Market Cap$13.37 million
Next Earnings Date3/4/2021 (Confirmed)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.19 out of 5 stars

Medical Sector

854th out of 1,956 stocks

Pharmaceutical Preparations Industry

418th out of 769 stocks

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.67
-0.02 (-3.07 %)
(As of 02/26/2021 02:19 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SYN News and Ratings via Email

Sign-up to receive the latest news and ratings for SYN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Synthetic Biologics (NYSEAMERICAN:SYN) Frequently Asked Questions

Is Synthetic Biologics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Synthetic Biologics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Synthetic Biologics stock.
View analyst ratings for Synthetic Biologics
or view top-rated stocks.

What stocks does MarketBeat like better than Synthetic Biologics?

Wall Street analysts have given Synthetic Biologics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Synthetic Biologics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Synthetic Biologics?

Synthetic Biologics saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 1,810,000 shares, an increase of 565.4% from the December 31st total of 272,000 shares. Based on an average daily trading volume, of 11,400,000 shares, the days-to-cover ratio is presently 0.2 days.
View Synthetic Biologics' Short Interest
.

When is Synthetic Biologics' next earnings date?

Synthetic Biologics is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for Synthetic Biologics
.

How were Synthetic Biologics' earnings last quarter?

Synthetic Biologics, Inc. (NYSEAMERICAN:SYN) issued its quarterly earnings data on Tuesday, November, 10th. The company reported ($0.14) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.17) by $0.03.
View Synthetic Biologics' earnings history
.

How has Synthetic Biologics' stock been impacted by COVID-19?

Synthetic Biologics' stock was trading at $0.36 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, SYN stock has increased by 88.1% and is now trading at $0.6770.
View which stocks have been most impacted by COVID-19
.

When did Synthetic Biologics' stock split? How did Synthetic Biologics' stock split work?

Synthetic Biologics shares reverse split on the morning of Monday, August 13th 2018. The 1-35 reverse split was announced on Wednesday, August 1st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 10th 2018. An investor that had 100 shares of Synthetic Biologics stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for SYN?

2 Wall Street analysts have issued 12 month price targets for Synthetic Biologics' stock. Their forecasts range from $1.25 to $1.50. On average, they anticipate Synthetic Biologics' share price to reach $1.38 in the next year. This suggests a possible upside of 103.1% from the stock's current price.
View analysts' price targets for Synthetic Biologics
or view top-rated stocks among Wall Street analysts.

Who are Synthetic Biologics' key executives?

Synthetic Biologics' management team includes the following people:
  • Mr. Steven A. Shallcross CPA, CEO, CFO, Treasurer, Corp. Sec. & Director (Age 60, Pay $989.81k)
  • Vincent I. Perrone, Director of Corp. Communication
  • Dr. Vince Wacher, Head of Product and Corp. Devel.
  • Dr. Michael Kaleko, Sr. VP of R&D
  • Ms. Lara M. Guzman, Sr. Director of Project Operations

Who are some of Synthetic Biologics' key competitors?

What other stocks do shareholders of Synthetic Biologics own?

What is Synthetic Biologics' stock symbol?

Synthetic Biologics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SYN."

Who are Synthetic Biologics' major shareholders?

Synthetic Biologics' stock is owned by a number of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (6.19%), Fisher Asset Management LLC (0.63%) and Virtu Financial LLC (0.52%). Company insiders that own Synthetic Biologics stock include Randal J Kirk and Steven A Shallcross.
View institutional ownership trends for Synthetic Biologics
.

Which institutional investors are buying Synthetic Biologics stock?

SYN stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC, and Fisher Asset Management LLC.
View insider buying and selling activity for Synthetic Biologics
or or view top insider-buying stocks.

How do I buy shares of Synthetic Biologics?

Shares of SYN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Synthetic Biologics' stock price today?

One share of SYN stock can currently be purchased for approximately $0.68.

How much money does Synthetic Biologics make?

Synthetic Biologics has a market capitalization of $13.54 million.

How many employees does Synthetic Biologics have?

Synthetic Biologics employs 11 workers across the globe.

What is Synthetic Biologics' official website?

The official website for Synthetic Biologics is www.syntheticbiologics.com.

Where are Synthetic Biologics' headquarters?

Synthetic Biologics is headquartered at 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States.

How can I contact Synthetic Biologics?

Synthetic Biologics' mailing address is 617 Detroit St Ste 100, ANN ARBOR, MI 48104-1125, United States. The company can be reached via phone at +1-734-3327800 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.